

Financials


(Dr. Cornelia
Ballwießer)



SUSS keeps moving

Our 2030 ambitions and the associated strategies are the baseline for our mid-term financial planning

Revenue development (in €M)



Growing Innovation

Sales growth driver

- Growth with our current portfolio, driven by attractive market growth in the addressable markets and market share gains
- Establishing in new markets through innovations (especially wafer cleaning, hybrid bonding, inkjet printing) and launching of next product generations
- More strategic installed base management

SUSS keeps moving


Our 2030 ambitions and the associated strategies are the baseline for our mid-term financial planning

Gross profit margin driver

- Execution of the modularization and platform strategy
- New products and innovations with above-average margins
- Cost-optimized production network and increased flexibility to adjust production capacity to demand
- Strategic installed base management and focused service product portfolio

**Growing
Innovation**

Gross profit margin development (in %)



1) Wafer Cleaning, Hybrid Bonding & Inkjet

R&D spend and CapEx for future success of SUSS



R&D spend

Focus on innovative solutions and follow-on product generations




CapEx

Supplying modern infrastructure to achieve long-term ambitions

R&D spending has been the main growth enabler at SUSS, while low average CapEx has led to a certain degree of underinvestment

R&D spending and CapEx 2018 – 2025e

Cumulated amounts 2018 – 2025 (in € m)



> CapEx

75.2

∅ CapEx/Sales ratio:
3%

> R&D spend

225.5


∅ R&D/Sales ratio:
9%

- Between 2018 and 2025, we spent a total of ~ €300 million in future growth of SUSS, of which 75% was allocated to R&D and 25% to CapEx
- Compared to the strong growth of SUSS in recent years, the expenditure for R&D (∅ 9% of sales) and CapEx (∅ 3% of sales) was rather low

¹ 2025e represents our R&D and CapEx expectations for the financial year 2025 as of 17th November 2025. ² MicroOptics segment included in the financial years 2018 to 2021; from 2022 onwards, only continuing operations are presented.

To continue the growth path, a steady increase in R&D spend will be necessary in the coming years

Cumulated amounts (R&D and CapEx)



- + Average annual CapEx level between 2026 and 2030 is likely to be between € 20 million and € 24 million, resulting to an average CapEx/sales ratio of 3.3%
- + The mid-term planning includes investment in a new state-of-the-art Application Center (tentatively scheduled for ~ 2027/2028) and investment in other infrastructure, also to support our decarbonization targets¹
- + Between 2026 and 2030, R&D spend will continue to rise steadily (especially from 2027) based on our product roadmap
- + Cumulatively, R&D expenses will amount to €360 to 380 million between 2026 and 2030; R&D ratio is expected to be at ~11% of sales in 2030

■ R&D spending ■ CapEx

¹: Our target is to achieve 100% carbon neutral business operations at all locations by 2030 (net zero greenhouse gas emissions in Scope 1 and 2)

The future success of SUSS will be evident in particular through sales growth and margin improvement

Sales growth


Between 2025 and 2030, we expect sales CAGR of 9% to 13%

Margin expansion

By 2030, we will enter a new gross profit and EBIT margin level for SUSS

Thanks to strong sales growth, particularly in recent years, the 2025 sales target of €400 million was already achieved in 2024

Sales development 2018 – 2025e




- We have managed to exceed the €400 million sales target set for 2025 already in 2024 – without the MicroOptics business, which has been sold in early 2024
- After a CAGR of 9.8 % between 2018 and 2023, growth momentum has increased significantly between 2023 and 2025 with a CAGR of > 24%, mainly driven by AI-related demand momentum, our focus on supporting large customers and improved Operations capabilities

¹ Since September 30, 2023, the MicroOptics segment has been reported as a discontinued operation in the financial reporting of SUSS and has therefore been removed from this multi-year overview of revenue development as of 2023.

Between 2025 and 2030, we expect average sales growth of 9 to 13%, with momentum picking up from 2027 onwards

Sales development 2024 – 2025e – 2030A




- 2026 will be a transitional year with an expected decline in sales, as the market has reached a certain level of saturation which has led to a rather low order intake in the first three quarters of 2025 (mainly AI-related bonder demand and continuation of muted demand for Photomask Solutions from China); improved order momentum expected for Q4 2025
- From 2027 onwards, we expect sales momentum to increase, also thanks to five product launches scheduled for 2026

¹ CAGR 2025e – 2030A based on the midpoint of the 2025 sales forecast

SUSS has significantly improved its margin profile since 2024, mainly due to its focus on semi-equipment business and large customers

Gross profit and EBIT margin in % 2018 – 2025e




- Between 2018 and 2023, gross profit margin averaged 33.8% and EBIT margin 7.1%; the main reasons for the weak margin profile were the MicroOptics segment (sold in 2024) defocusing on the core business, excessive complexity overall and inefficiencies in Operations
- Due to an increased business volume with a good product and customer mix and considerable operational improvements, we managed to improve the margin profile in recent years although 2024 can be considered exceptional due to the very high proportion of AI-related orders

¹ Adjusted for the MicroOptics segment, which has been considered as a discontinued operation since September 30, 2023; ² Calculated on the basis of the midpoint of the 2025 margin forecast

There is significant potential for further margin expansion, particularly driven by scheduled portfolio changes in our segments


Gross profit and EBIT margin in % 2024 – 2025e – 2030A



- Based on our strategic plan for 2030, we see the potential to increase the gross profit margin to 43 – 45%, in particular due to the changes in the product portfolio of both business units
- The improvement in EBIT margin to 20-22% is supported by a higher gross profit and a disproportionate increase in SG&A expenses compared to sales

EBIT margin to benefit from higher business volume while increased R&D spend is covered by decline of SG&A expense ratio


How to achieve the targeted EBIT margin of 20 – 22%



Benefiting from increase in gross profit

Gross profit has the potential to ~ **double** from 2024 to 2030, driven by larger business volume with improved profitability

¹ Gross profit is calculated based on the mid-point of the 2030 sales ambition.



Reduced SG&A expense ratio projected

- **R&D expense ratio** is expected to increase to support sales growth
- **SG&A expense ratio** is expected to decrease by ~ 2 to 3 %-points due to below-average increase in selling costs and admin functions

■ R&D expense ratio
■ SG&A expense ratio

Based on our strategic financial model, Operating Cashflow and Free Cashflow are both expected to reach significantly higher levels in 2030




Cash flow generation

We plan to significantly improve **Operating and Free Cashflow** in the coming years – with a significant **improvement** by the end of the decade.


After strong fluctuations in 2019 and 2020, Operating and Free Cashflow have stabilized significantly

Operating CF, CapEx and Free Cashflow 2018 – 2024



By the end of the decade, significantly higher levels of Operating CF and Free CF can be used to finance growth beyond 2030

Operating CF, CapEx¹ and Free Cashflow 2024 – 2030A



Operating Cashflow CapEx Free Cashflow

¹ CapEx program up to 2030 may change as measures are prioritized over the course of the period, including the amount and timing of planned projects.
Note: The dotted line from 2028 to 2030 indicates the possible development of Free CF in the event of major investments to support growth beyond 2030.

Generating shareholder value is a clear objective of our strategic plan for the period up to 2030




Shareholder return

It is our clear target to generate **shareholder value**, which is reflected in rising EPS and Free Cashflow per share. In terms of capital allocation, our primary goal remains to finance future growth and maintain a solid balance sheet structure.

We have distributed dividends totaling €16.4 million to our shareholders for the years 2021 to 2024


Dividend distribution 2021 – 2024

(in € per share; payment in the following year)



Dividend payments 2021 – 2024

(in € million; payment in the following year)



SUSS adopted a **dividend policy** for the first time in March 2022; first dividend payment therefore for the 2021 fiscal year.


Total dividend payments for the fiscal years 2021 to 2024 amounted to **€16.4 million**.



Dividend policy

- Our **shareholders** should participate in the company's success through reliable and appropriate distributions
- At the same time, the **company** should have sufficient financial resources for its operating business and strategic investments and maintain an appropriate equity ratio
- Dividend reference value: Distribution of 20 to 40% of consolidated Free cash flow

Based on our ambitions for 2030, we expect to generate significantly more value for our shareholders



¹ 2024 EPS and Free Cashflow per share based on continuing operations.

² This scenario is based on achieving the respective midpoints of the 2030 ambitions for sales, gross profit margin, and EBIT margin.

We want to maintain sufficient liquidity to safeguard our targeted business growth and to buffer cash flow volatility

Solid liquidity position

We continue to consider a cash availability of ~ 25% of annual sales to be solid and typical for our industry




Solid capital structure and high credit score

- After an equity ratio of 55.9% in 2024, we expect an increase in the coming years
- We want to maintain a healthy balance sheet structure and constantly improve our credit score



Our top priority for capital allocation is future investments that support targeted growth

Invest to support targeted organic growth,
primarily through R&D spend and CapEx



Maintain and further strengthen balance sheet
to enable flexible funding of growth-related activities



Finance potential inorganic growth
through more concrete scouting and execution of M&A opportunities



Our shareholders participate in our success
mainly through dividends



Our ambition is to take SUSS to a new financial level by 2030

	FY 2024	FY 2030A
Sales	€446.1 million	€750 – 900 million
Sales growth	46.6% (YoY)	9 to 13% (CAGR 2025 – 2030A ¹)
Gross profit margin (in %)	40%	43 to 45%
SG&A (in % of sales)	13.8%	~11 to 12%
R&D (in % of sales)	9.0%	~11%
EBIT margin (in %)	16.8%	20 to 22%
Free Cashflow	€25.3 million	~ €90 million
ROCE	36.8%	39 to 41%
CapEx	€7.6 million	~ €22 million (annual ø 2026 – 2030)
Tax rate	33.1%	~28% ²

¹ The CAGR calculation is based on the midpoint of the 2025 sales forecast, i.e., € 490 million; ² The internal planning assumption for the tax rate is generally ~ 28%.

Disclaimer

The following presentations contain forward-looking statements relating to the business, financial performance and earnings of SUSS MicroTec SE and its subsidiaries and associates.

Forward-looking statements are based on current plans, estimates, projections and expectations and are therefore subject to risks and uncertainties, most of which are difficult to estimate and which in general are beyond the control of SUSS MicroTec SE. Consequently, actual developments as well as actual earnings and performance may differ materially from those which explicitly or implicitly assumed in the forward-looking statements.

SUSS MicroTec SE does not intend or accept any obligation to publish updates of these forward-looking statements.